Comparing Two Chemotherapy Treatments for Breast Cancer
Author Information
Author(s): Harper-Wynne C, English J, Meyer L, Bower M, Archer C, Sinnett H D, Lowdell C, Coombes R C
Primary Institution: Department of Medical Oncology, Cancer Research Campaign Laboratories, Imperial College School of Medicine, Charing Cross Hospital
Hypothesis
Is the combination of methotrexate and mitoxantrone more effective and less toxic than cyclophosphamide, methotrexate, and 5-fluorouracil in treating advanced breast cancer?
Conclusion
While the methotrexate and mitoxantrone regimen showed fewer side effects, it did not significantly improve overall survival or response rates compared to the CMF regimen.
Supporting Evidence
- Objective responses occurred in 29% of patients receiving CMF and 15% receiving MM.
- Significantly reduced haematological toxicity and alopecia were observed in the MM group.
- No significant differences in quality of life were found between the two treatment regimens.
Takeaway
Doctors tested two different treatments for breast cancer to see which one works better and has fewer side effects. One treatment was easier on patients, even if it didn't help them live longer.
Methodology
Patients were randomized to receive either CMF or MM as first-line chemotherapy treatment.
Limitations
No statistically significant differences in overall survival or time to progression were found between the two treatments.
Participant Demographics
Patients with locally advanced or metastatic breast cancer.
Statistical Information
P-Value
0.07
Confidence Interval
–1%–29%
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website